FourThought Financial’s Corcept Therapeutics CORT Stock Holding History

FourThought Financial’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$318K	Hold	12,406	–	–	0.05%	237
2022 Q2	$295K	Hold	12,406	–	–	0.04%	267
2022 Q1	$279K	Hold	12,406	–	–	0.04%	284
2021 Q4	$246K	Hold	12,406	–	–	0.03%	311
2021 Q3	$244K	Hold	12,406	–	–	0.03%	307
2021 Q2	$272K	Hold	12,406	–	–	0.04%	304
2021 Q1	$295K	Sell	12,406 -7,659	-38%	-$204K	0.04%	288
2020 Q4	$524K	Buy	+20,065	New	+$423K	0.08%	186

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FourThought Financial's CORT Position: Q3 2022 in Review

FourThought Financial held its Corcept Therapeutics (CORT) position steady in Q3 2022 at 12,406 shares worth $318K. The position accounts for 0.05% of the portfolio, ranked #237.

FourThought Financial first reported a position in CORT in Q4 2020 and has held it in 8 quarters since. The position peaked at $524K in Q4 2020. 239 funds tracked by Wall St. Rank hold CORT as of Q3 2022.

FourThought Financial held 12,406 shares of Corcept Therapeutics worth $318K as of Q3 2022.
FourThought Financial left its Corcept Therapeutics share count unchanged in Q3 2022.
Corcept Therapeutics made up 0.05% of FourThought Financial's portfolio in Q3 2022, its #237 holding.
FourThought Financial first reported a position in Corcept Therapeutics in Q4 2020 and has held it in 8 quarters since.
FourThought Financial's Corcept Therapeutics position peaked at $524K in Q4 2020.
239 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.